Want to join the conversation?
The biotechnology company $CELG reported a 3Q15 loss due to higher costs on Juno Therapeutics collaboration and expenses on purchase of Receptos. Net loss was $34.1MM or $0.04 per share compared to a profit of $508.5MM or $0.61 per share last year. Revenue grew to $2.33Bil from $1.98Bil. Adjusted EPS rose to $1.23 from $0.97.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.